NovaDel Pharma's Third Foreign Patent Issued

NovaDel Pharma's Third Foreign Patent Issued 


FLEMINGTON, N.J., April 22  /PRNewswire-FirstCall/ -- NovaDel Pharma Inc. 
(BULLETIN BOARD: NVDL)  said it was awarded Greek Patent No.GR0904055 covering
its linqual spray drug delivery technology for non-polar products. NovaDel's
technology is widely applicable to a variety of drugs for which fast onset of
therapeutic activity and reduction of first pass hepatic toxicity are
consideration key product attributes.

"This patent, which is our third issued internationally, joins five issued US
patents in broadening our IP assets," said Gary A. Shangold, MD, chief
executive officer of NovaDel.  "We currently have 29 patent applications
pending in the US, Canada, the EU and Japan, concerning methods of delivery of
a variety of therapeutic classes and specific drugs within those classes."

About NovaDel Pharma Inc.

NovaDel Pharma Inc. is a specialty pharmaceutical company engaged in the
development of novel drug delivery systems for prescription and
over-the-counter drugs.  The Company's proprietary lingual spray technology
delivery system offers the patient (i) fast onset of action; (ii) improved drug
safety by reducing the required drug dosage and reducing side effects; (iii)
improved patient convenience and compliance; and (iv) enhanced dosage
reliability.  The Company plans to develop such products independently and
through collaborative arrangements with major pharmaceutical and biotech
companies.

Except for historical information contained herein, this document contains
forward-looking statements within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements involve known and unknown risks
and uncertainties that may cause the Company's actual results or outcomes to be
materially different from those anticipated and discussed herein including, but
not limited to, the ability to develop products (independently and through
collaborative arrangements), and the ability to commercialize and obtain
approval for products under development. Further, the Company operates in
industries where securities may be volatile and may be influenced by regulatory
and other factors beyond the Company's control. Important factors that the
Company believes might cause such differences are discussed in the risk factors
detailed in the Company's most recent Annual Report and Registration
Statements, filed with the Securities and Exchange Commission.  In assessing
forward-looking statements contained herein, if any, the reader is urged to
carefully read all cautionary statements contained in such filings.

   Contact:
   Barry C. Cohen
   VP Business & New Product Development
   908 782-3431 x 2160
   NovaDel Pharma Inc.

   Thomas Redington
   203 222-7399
   212 926-1733
   

DATASOURCE: NovaDel Pharma Inc.



CONTACT:  Barry C. Cohen, VP Business & New Product Development of

NovaDel Pharma Inc., [phone], ext. 2160; or Thomas Redington,

[phone], or [phone], or , for

NovaDel Pharma Inc.

Copyright